Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: an analysis of the Pulmonary Hypertension Association Registry.
health-care utilization
pulmonary hypertension
socioeconomic status
Journal
Pulmonary circulation
ISSN: 2045-8932
Titre abrégé: Pulm Circ
Pays: United States
ID NLM: 101557243
Informations de publication
Date de publication:
Historique:
entrez:
23
6
2021
pubmed:
24
6
2021
medline:
24
6
2021
Statut:
epublish
Résumé
Compared to idiopathic pulmonary arterial hypertension (IPAH), patients with portopulmonary hypertension (POPH) have worse survival. Health disparities may contribute to these differences but have not been studied. We sought to compare socioeconomic factors in patients with POPH and IPAH and to determine whether socioeconomic status and/or POPH diagnosis were associated with treatment and health-care utilization. We performed a cross-sectional study of adults enrolled in the Pulmonary Hypertension Association Registry. Patients with IPAH (n = 344) and POPH (n = 57) were compared. Compared with IPAH, patients with POPH were less likely to be college graduates (19.6% vs. 34.9%, p = 0.02) and more likely to be unemployed (54.7% vs. 30.5%, p < 0.001) and have an annual household income below poverty level (45.7% vs. 19.0%, p < 0.001). Patients with POPH had similar functional class, quality of life, 6-min walk distance, and mean pulmonary arterial pressure with a higher cardiac index. Compared with IPAH, patients with POPH were less likely to receive combination therapy (46.4% vs. 62.2%, p = 0.03) and endothelin receptor antagonists (28.6% vs. 55.1%, p < 0.001) at enrollment with similar treatment at follow-up. Patients with POPH had more emergency department visits (1.7 ± 2.1 vs. 0.9 ± 1.2, p = 0.009) and hospitalizations in the six months preceding enrollment (1.5 ± 2.1 vs. 0.8 ± 1.1, p = 0.02). Both POPH diagnosis and lower education level were independently associated with a higher number of emergency department visits. Compared to IPAH, patients with POPH have lower socioeconomic status, are less likely to receive initial combination therapy and endothelin receptor antagonists but have similar treatment at follow-up, and have increased health-care utilization.
Identifiants
pubmed: 34158918
doi: 10.1177/20458940211020913
pii: 10.1177_20458940211020913
pmc: PMC8186121
doi:
Types de publication
Journal Article
Langues
eng
Pagination
20458940211020913Commentaires et corrections
Type : ErratumIn
Informations de copyright
© The Author(s) 2021.
Références
Eur Respir J. 2017 Aug 3;50(2):
pubmed: 28775050
Chest. 2010 Feb;137(2):376-87
pubmed: 19837821
Liver Transpl. 2000 Jul;6(4):443-50
pubmed: 10915166
Pulm Circ. 2016 Jun;6(2):191-5
pubmed: 27252845
Eur Respir J. 2019 Jan 24;53(1):
pubmed: 30545968
Liver Transpl. 2020 Jul;26(7):935-940
pubmed: 32150762
Eur Respir J. 2004 Nov;24(5):861-80
pubmed: 15516683
J Am Heart Assoc. 2016 Oct 26;5(11):
pubmed: 27912207
Chest. 2020 Jul;158(1):330-340
pubmed: 32109446
Transplantation. 2016 Jul;100(7):1440-52
pubmed: 27326810
J Heart Lung Transplant. 2020 May;39(5):464-472
pubmed: 32008947
Liver Transpl. 2000 Mar;6(2):241-2
pubmed: 10719028
Qual Life Res. 2020 Nov;29(11):2977-2986
pubmed: 32621260
Chest. 2019 Aug;156(2):323-337
pubmed: 30772387
Pulm Circ. 2020 Nov 23;10(4):2045894020962917
pubmed: 33282188
N Engl J Med. 2015 Aug 27;373(9):834-44
pubmed: 26308684
Lancet Respir Med. 2019 Jul;7(7):594-604
pubmed: 31178422
Am J Transplant. 2008 Nov;8(11):2445-53
pubmed: 18782292
Mayo Clin Proc. 2011 Feb;86(2):105-12
pubmed: 21282484
Chest. 2012 Apr;141(4):906-915
pubmed: 21778257
Am J Respir Crit Care Med. 2017 Oct 15;196(8):e32-e47
pubmed: 29028375
JACC Heart Fail. 2018 Jun;6(6):465-473
pubmed: 29852931
J Am Coll Cardiol. 2006 Feb 21;47(4):799-803
pubmed: 16487848
Ann Am Thorac Soc. 2017 May;14(5):814-826
pubmed: 28459618
J Heart Lung Transplant. 2017 Jul;36(7):770-779
pubmed: 28190786
Eur Respir J. 2019 Jan 24;53(1):
pubmed: 30545971